The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tissue Engineering: The End of the Beginning
Abstract
This study was undertaken to assess the impact of current economic conditions and recent disappointing product launches on the field of tissue engineering. Data were collected on all firms known to be active in the field, analyzed, and compared with analogous data collected in 1995, 1998, and 2000. As of December 31, 2002, more than 2600 full-time equivalents (FTEs) in 15 countries and 89 firms were engaged in tissue-engineering research and development. Annual spending was US dollars 487 million, down about 20% since 2000-a reasonable performance in the face of a stagnant economy and difficult capital markets. Individual sectors proved far more volatile. Activity in skin, cartilage, and other structural applications declined by more than 50% with a loss of 800 FTEs. This downsizing was somewhat counterbalanced by a 42% increase in stem cell firms, which added more than 300 employees. Consistent with general disenchantment with technology sector equities, capital value of publicly traded tissue-engineering corporations has decreased by almost 90% from US dollars 2.5 billion at the end of 2000 to US dollars 300 million at the end of 2002. The United States' fraction of the total workforce declined from 80% in 2000 to 54% in 2002. By the close of 2002, twenty tissue-engineered products had entered Food and Drug Administration clinical trials. Four were approved but none of these are yet commercially successful. Six other applications were either abandoned or failed to achieve product approval. Ten products were still in clinical trials, some of which were investigator sponsored, and most of which were at the phase I/phase II stage. The field has yet to produce a profitable product despite an aggregate research and development investment exceeding US dollars 4.5 billion. Tissue engineering is clearly having difficulty transitioning from a development stage industry to one with a successful product portfolio. This is often the case for breakthrough medical technologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why tissue engineering needs process engineering
Archer, R., & Williams, D. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1105-1353 · Cited by 101
Cited by
Capturing complex 3D tissue physiology in vitro
Griffith, L. G., & Swartz, M. A. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1858 · Cited by 2,290
Additive manufacturing of tissues and organs
Melchels, F. P. W., Domingos, M. A. N., Klein, T. J., Malda, J., Bartolo, P. J., & Hutmacher, D. W. (2012) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.11.007 · Cited by 1,213
Badylak, S. F., Taylor, D., & Uygun, K. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124743 · Cited by 1,041
Tissue Engineering and Regenerative Medicine: History, Progress, and Challenges
Berthiaume, F., Maguire, T. J., & Yarmush, M. L. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114257 · Cited by 734
Evaluation of polycaprolactone scaffold degradation for 6 months in vitro and in vivo
Lam, C. X. F., Hutmacher, D. W., Schantz, J., Woodruff, M. A., & Teoh, S. H. (2009) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32052 · Cited by 599
Metadata
- Authors
- Lysaght, M. J., & Hazlehurst, A. L.
- Venue
- Tissue Engineering
- Publisher
- SAGE Publications
- Published
- 2004-01
- Volume
- 10
- Issue
- 1-2
- Pages
- 309-320
- ISSN
- 1076-3279 (ISSN-L)
- 1557-8690
- OpenAlex
- W2175838564
- Cited by
- 238
- References
- 1
- FWCI
- 25.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tissue Engineering: The End of the Beginning. https://app.cochat.ai/papers/10.1089/107632704322791943
- The paper
- Lysaght, M. J., & Hazlehurst, A. L. (2004). Tissue Engineering: The End of the Beginning. Tissue Engineering. https://doi.org/10.1089/107632704322791943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.